BMS Receives CHMP Opinion for Opdivo® & Yervoy® in MSI-H mCRC
15 Nov 2024 //
BUSINESSWIRE
Arbutus & Barinthus Report Nivolumab raise HBsAg Loss in Hepatitis B
15 Nov 2024 //
GLOBENEWSWIRE
Replimune Presents RP1 + Nivolumab Data in Failed Melanoma
09 Nov 2024 //
GLOBENEWSWIRE
HUYABIO Presents Phase 2 Data on HBI-8000 + Nivolumab in Melanoma
08 Nov 2024 //
PR NEWSWIRE
BMS` Opdivo joins lung cancer treatment ring with key FDA approval
04 Oct 2024 //
FIERCE PHARMA
Bristol Myers`s Biologic Opdivo (Nivolumab) Receives Suppl Approval in US
03 Oct 2024 //
FDA
BMS Shows 10-Year Survival Data For Opdivo-Yervoy In Advanced Melanoma
15 Sep 2024 //
BUSINESSWIRE
Replimune Presents RP1 Data In Anti-PD1 Failed Melanoma At ESMO 2024
15 Sep 2024 //
GLOBENEWSWIRE
ImmunityBio Reports NSCLC Survival Data, Plans Phase 3 Trials
09 Sep 2024 //
BUSINESSWIRE
Ultimovacs Updates On UV1 Phase II NIPU Trial At ESMO 2024
08 Sep 2024 //
GLOBENEWSWIRE
BMS Receives FDA sBLA Acceptance For Hepatocellular Carcinoma Drug
22 Aug 2024 //
BUSINESSWIRE
Replimune Doses First Patient In IGNYTE-3 Melanoma Trial
13 Aug 2024 //
GLOBENEWSWIRE
BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer
20 Jul 2024 //
PRESS RELEASE
EMA Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
21 Jun 2024 //
BUSINESSWIRE
US study suggests BMS’ cancer drug could target Parkinson’s-causing protein
20 Jun 2024 //
PHARMATIMES
I-Mab and BMS assess givastomig for gastric and oesophageal cancer
06 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Replimune Announces Positive IGNYTE Data Of RP1 Plus Nivolumab In Melanoma
06 Jun 2024 //
GLOBENEWSWIRE
ASCO: Bristol calls Roche and AZ`s bets in 1L liver cancer
04 Jun 2024 //
FIERCE PHARMA
BMS` Opdivo Combo Data In Early, Advanced NSCLC At ASCO 2024
03 Jun 2024 //
BUSINESSWIRE
Pre-surgery treatment with BMS combination therapy leads to better skin cancer
03 Jun 2024 //
REUTERS
BMS secures another EC approval for Opdivo combination
30 May 2024 //
PHARMACEUTICALS-TECHNOLOGY
BMS` triplet, Iovance`s Amtagvi-Keytruda target melanoma
24 May 2024 //
FIERCE PHARMA
Xbrane successfully scales up Xdivane™- biosimilar candidate to Opdivo®
22 May 2024 //
PRESS RELEASE
Bristol Myers` subcutaneous version of Opdivo gets earlier PDUFA date
22 May 2024 //
PRESS RELEASE
Halozyme: BMS Gets FDA Date For Nivolumab-ENHANZE
21 May 2024 //
PR NEWSWIRE
As Bristol Myers reveals trial failure, AstraZeneca`s Imfinzi stays king in stage 3 lung cancer
14 May 2024 //
FIERCE PHARMA
FDA decision on BMS’s subcutaneous Opdivo set for early next year
07 May 2024 //
PRESS RELEASE
EMA Validates BMS’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab)
06 May 2024 //
PRESS RELEASE
Bristol Myers to cut 6% of workforce, trim drug pipeline
25 Apr 2024 //
BIOPHARMADIVE
PDIVO Nivolumab Pipeline Report 2024: First IgG4 PD-1 Inhibitor Antibody
18 Apr 2024 //
BUSINESSWIRE
Ultimovacs lays off 40% in wake of cancer vaccine`s phase 2 fail
17 Apr 2024 //
FIERCE BIOTECH
Bristol Myers` Opdivo-Yervoy combo meets main goal in liver cancer trial
21 Mar 2024 //
REUTERS
FDA Approves Opdivo for First-Line Treatment of Urothelial Carcinoma
07 Mar 2024 //
BUSINESSWIRE
Ultimovacs Announces Results from INITIUM Study Evaluating UV1 Vaccination
07 Mar 2024 //
GLOBENEWSWIRE
BMS Announces Acceptance of U.S. & EU Regulatory Filings for Neoadjuvant Opdivo
07 Feb 2024 //
BUSINESSWIRE
Bristol Myers reveals subcutaneous Opdivo data in kidney cancer as I-O battle heads to new front
30 Jan 2024 //
FIERCE PHARMA
Subcutaneous Nivolumab Shows Noninferiority Compared to Intravenous Opdivo in ccRCC
27 Jan 2024 //
BUSINESSWIRE
SELLAS Life Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S
27 Dec 2023 //
GLOBENEWSWIRE
Bristol Myers scraps Opdualag trial in colorectal cancer
18 Dec 2023 //
FIERCE PHARMA
ASH: Adcetris, Opdivo boost hopes for another ADC, PD-1 combo
10 Dec 2023 //
FIERCE PHARMA
BMS`s Opdivo-Yervoy excels in first-line colorectal cancer trial
08 Dec 2023 //
FIERCE PHARMA
BMS Announces Phase 3 Trial Evaluating Opdivo in Microsatellite Instability
07 Dec 2023 //
BUSINESSWIRE
FDA Accepts for Priority Review BMS’ Application for Opdivo for Urothelial Carcinoma
05 Dec 2023 //
BUSINESSWIRE
EMA Validates Application for Opdivo for First-Line Treatment of Urothelial Carcinoma
30 Oct 2023 //
PRESS RELEASE
First Patient Enrolled in Phase III Clinical Trial of Boan Biotech`s Nivolumab Injection
30 Oct 2023 //
ASIAONE
ESMO: BMS` Opdivo bladder cancer win overshadowed
22 Oct 2023 //
FIERCE PHARMA
Bristol Myers` injectable form of Opdivo meets main goal in kidney cancer trial
20 Oct 2023 //
PRESS RELEASE
BMS`s Opdivo claims more of the melanoma pie
16 Oct 2023 //
FIERCE PHARMA
FDA Approves Opdivo as Adjuvant Treatment for Stage IIB or Stage IIC Melanoma1
13 Oct 2023 //
BUSINESSWIRE
FDA Approves Adjuvant Nivolumab for Completely Resected Stage IIB/C Melanoma
13 Oct 2023 //
ONCLIVE
Amgen readies PhIII trial for first Opdivo biosimilar
27 Sep 2023 //
ENDPTS
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo
22 Sep 2023 //
BUSINESSWIRE
Neoadjuvant Nivolumab/Ipilimumab Combo Elicits Responses in Resectable HCC
13 Sep 2023 //
ONCLIVE
Phase 3 Show Survival with Opdivo Plus Yervoy in First-Line Treatment for NSCLC
11 Sep 2023 //
BUSINESSWIRE